Opportunity for broader impact as 70% of key
opinion leaders interact with only one biopharma
BARCELONA, Spain, July 26, 2023 /PRNewswire/ -- Veeva Systems
(NYSE: VEEV) today revealed findings of field medical's impact on
clinical practice in the Veeva Pulse Field Trends Report. Analysis
shows that disease state education by medical science liaisons
(MSLs) with key opinion leaders (KOLs) before launch leads to 1.5
times greater treatment adoption. This result across the healthcare
organization (HCO) within the first six months post-launch expands
reach to more patients that could benefit from new medicines and
therapies.
Scientific engagement with KOLs has a lasting impact on new
treatment adoption and most KOLs are asking for more interactions
with MSLs. Yet, 70% only engage with one company's field medical
team. The lack of breadth in KOL engagement indicates a need for
greater field planning and connected insights across the
organization to identify and prioritize engagement with key
experts.
"The right data is foundational to our engagement strategy. We
can quickly identify who the relevant KOLs are, and organize those
KOLs based on when and where they are sharing scientific
information and what scientific information they are sharing," said
Christine Castro, director of
medical affairs excellence at Lundbeck. "As we prepared for the
launch of new treatments, this data-driven approach helped us build
the right relationships and focus our resources where they will
have the greatest scientific impact."
Veeva Pulse analysis shows pre-launch field medical educational
engagement with KOLs has a measurable benefit on new treatment
adoption:
- MSL engagement with KOLs before launch drives 1.5 times
greater treatment adoption. Scientific engagement with
KOLs, either in-person or video, increases new patient starts
within the first six months post-launch.
- New treatment starts sustain at 1.3 times greater 18 to 24
months after product launch. Engagement with MSLs before launch
has long-term impact helping KOLs consistently identify and reach
the right patients with the right treatment.
- Despite the value of medical field interaction, 70% of KOLs
engage with only one biopharma. While the depth of individual
connections may be substantial, the breadth of KOL engagement is
not. An additional 30% of global experts, as identified in Veeva
Link Key People, have no recorded interaction with MSLs at all.
This limits scientific exchange, medical insights, and potential
treatment adoption by patients in need.
"This deeper understanding of scientific engagement and
treatment adoption shows the impact of field medical on launch
success and most KOLs have greater potential to work with more
field medical representatives to get the right medicine to the
right patients faster," said Aaron
Bean, vice president of Veeva commercial business
consulting, Europe.
About the Veeva Pulse Field Trends Report
Analyzing over 600 million HCP interactions and activities annually
from more than 80% of commercial biopharma field teams worldwide,
the Veeva Pulse Field Trends Report is the largest industry
benchmark of its kind on HCP engagement. The analysis compiles
real-time transactional data recorded in Veeva CRM and data
products in Veeva Commercial Cloud to deliver a view of engagement
activity across life sciences. Indexed by Veeva quarterly, the data
will help companies effectively and accurately benchmark
performance to set the right, actionable goals for continued growth
and impact.
Additional Information
To download a copy of the Veeva
Pulse Field Trends Report, visit: veeva.com/eu/FieldTrends
Learn more about Veeva Business Consulting:
veeva.com/eu/BusinessConsulting
Connect with Veeva on LinkedIn:
linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
biopharmaceutical companies to emerging biotechs. As a Public
Benefit Corporation, Veeva is committed to balancing the interests
of all stakeholders, including customers, employees, shareholders,
and the industries it serves. For more information,
visit veeva.com/eu.
Veeva Forward-looking Statements
This release contains
forward-looking statements regarding Veeva's products and
services and the expected results or benefits from use of
our products and services. These statements are based on
our current expectations. Actual results could differ
materially from those provided in this release and we have no
obligation to update such statements. There are numerous
risks that have the potential to negatively impact
our results, including the risks and uncertainties disclosed
in our filing on Form 10-Q for the period ended April 30, 2023, which you can
find here (a summary of risks which may impact our
business can be found on pages 37 and 38), and in our subsequent
SEC filings, which you can access at sec.gov.
Contact:
Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com
Photo -
https://mma.prnewswire.com/media/2161410/Field_medical_impact_on_launch_success.jpg
Photo -
https://mma.prnewswire.com/media/2161409/Percent_of_KOLs_that_only_interact_with_one_biopharma.jpg
Logo -
https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/veeva-pulse-uncovers-field-medical-engagement-drives-1-5x-increase-in-treatment-adoption-301885555.html